

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精 優 藥 業 控 股 有 限 公 司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00858)

CHANGE OF CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) would like to announce that, for the purposes of segregation of duties, meeting the development requirements of the Company and to achieve the corporate governance enhancements, with effect from 1 January 2026:

- (1) Dr. Xie Yi (“**Dr. Xie**”) will resign as the chief executive officer of the Company (“**CEO**”) in order to focus on developing strategies of the Company. Dr. Xie will continue to be the Chairman of the Board (the “**Chairman**”) and an executive Director after his resignation as CEO; and
- (2) Dr. Guo Yi (“**Dr. Guo**”), an executive Director, will be appointed as the CEO.

Dr. Xie has confirmed that he has no disagreement with the Board, and there is no matter in relation to his resignation as CEO that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Biographical Details and Other Information of Dr. Guo

Dr. Guo, aged 44, obtained a bachelor degree in science (with a major in biology) and a doctorate degree in science (with a major in genetics) from the School of Life Sciences of Fudan University in 2003 and 2011 respectively. Dr. Guo has extensive experience in the fields of genetics, health care management, investment management and development for venture in biomedicine and has been committing his time and working in investment management and project development in the fields of biomedicine, medical devices and diagnostic services since August 2015. Dr. Guo was a non-executive director (from 8 June 2011 to 26 April 2012) and an executive director (from 27 April 2012 to 13 December 2015) of United Gene High-Tech Group Limited (now known as Starcoin Group Limited) whose shares are listed on the Main Board of the Stock Exchange (stock code: 399). He is currently the managing partner of Shanghai Rui Jian Venture Capital Management Co., Ltd.* (上海睿寬創業投資管理有限公司), a company established in the People’s Republic of China.

Dr. Guo was appointed as an independent non-executive Director on 14 April 2023 and was redesignated as an executive Director with effect from 7 June 2024. Dr. Guo is also a director of certain subsidiaries of the Group.

Dr. Guo will not enter into a separate agreement with the Company nor will he be entitled to receive additional remuneration for his appointment as CEO. Dr. Guo has entered into a letter of appointment with the Company as executive Director for a term commencing from the date of his appointment until terminated by either party by giving not less than two months' notice in advance, and shall be subject to retirement by rotation and re-election at the Company's annual general meeting in accordance with the bye-laws of the Company. Dr. Guo is currently entitled to a monthly salary of HK\$50,000 and a year-end bonus of an amount equivalent to his one month's salary and a director's fee in the amount of HK\$70,000 per annum, which was approved by the Board pursuant to the recommendation by the remuneration committee of the Board, with reference to his background, qualifications, experience, his roles and responsibilities within the Company and the prevailing market conditions.

As at the date of this announcement, Dr. Guo is entitled to 25,500,000 share options granted by the Company pursuant to the Company's share option scheme adopted on 2 September 2022. The underlying shares in respect of the 25,500,000 share options represent 1% of the issued shares of the Company as at the date of this announcement.

Save as disclosed above, as at the date of this announcement, Dr. Guo does not (i) hold any directorship in any other listed companies on the Stock Exchange and any other stock exchange during the three years preceding the date of this announcement; (ii) have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong; (iii) have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")); (iv) hold any other position in the Company or any of its subsidiaries; and (v) have other major appointments or professional qualifications save as disclosed herein.

Save as disclosed above, the Company is not aware of any other information relating to the appointment of Dr. Guo as CEO required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to (2)(v) of the Listing Rules or any other matter that needs to be brought to the attention of the Shareholders.

The Board would like to express its gratitude to Dr. Xie for his valuable contributions to the Group during his tenure of office as the CEO while acting as the Chairman and executive Director at the same time, and also extend its sincere appreciation to Dr. Guo for his new role as the CEO.

Upon the aforesaid change in CEO becoming effective from 1 January 2026, the roles of Chairman and CEO have been separately performed by Dr. Xie and Dr. Guo respectively. It follows that the Company has been in full compliance with Code Provision C.2.1 of Part 2 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules with effect from 1 January 2026.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 30 December 2025

As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Dr. Guo Yi, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Zeng Li.

* *For identification purpose only*